First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

Peters, Solange; Scherpereel, Arnaud; Cornelissen, Robin; Oulkhouir, Youssef; Greillier, Laurent; Ma, Kaplan; Talbot, Thomas; Monnet, I.; Hiret, Sandrine; Baas, P.; Nowak, Anna K.; Fujimoto, Nobukazu; Tsao, Anne S.; Mansfield, Aaron S.; Popat, Sanjay; Zhang, X.; Hu, Nan; Balli, David; Spires, Thomas; Zalcman, Gérard

doi:10.1016/j.annonc.2022.01.074

articleAnnals of OncologyFeb 3, 2022HYBRID OA

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

SPSolange Peters ASArnaud Scherpereel RCRobin Cornelissen YOYoussef Oulkhouir LGLaurent Greillier

University Hospital of Lausanne · Hôpital Orthopédique de la Suisse Romande · +36 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

•With a ≥3-year follow-up in CheckMate 743, nivolumab + ipilimumab continued to provide long-term OS benefit in first-line MPM.•Clinical benefits remained consistent across patient subgroups, including epithelioid versus non-epithelioid histology.•Discontinuing nivolumab + ipilimumab due to TRAEs did not negatively impact long-term benefit.•Nivolumab + ipilimumab continues to be an efficacious first-line treatment option for patients with unresectable MPM. BackgroundIn the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data…

Citation impact

260

total citations

FWCI: 35.96
Percentile: 100%
References: 48

Citations per year

Authors

20

Topics & keywords

Topics

Keywords

Medicine
Nivolumab
Ipilimumab
Internal medicine
Pemetrexed
Hazard ratio
Oncology
Chemotherapy

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.